Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of July 2025, specifically detailing share repurchases executed on July 16, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases conducted as part of an existing buyback program. No revenue, profit, or cash flow data is provided in this specific filing.
- Date of Purchase: July 16, 2025
- Aggregate Shares Purchased: 482,507 ordinary shares
- Share Class: Ordinary shares of 31½ pence each
- Lowest Price Paid: 1,398.00 GBp
- Highest Price Paid: 1,430.50 GBp
- Volume-Weighted Average Price (VWAP): 1,419.08 GBp
- Trading Venue: London Stock Exchange (XLON)
- Broker: Merrill Lynch International
Material Changes and Program Status
The purchase was executed pursuant to a non-discretionary agreement entered into on June 4, 2025. Since the inception of this agreement on June 4, 2025, the Company has purchased a total of 13,692,680 ordinary shares.
Following the July 16 transaction:
- Treasury Shares Held: 231,827,063 ordinary shares
- Shares in Issue (excluding Treasury): 4,083,556,994 ordinary shares
- Total Voting Rights: 4,083,556,994
- Treasury Voting Rights Percentage: 5.68% (in accordance with DTR 5.5.1R)
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,083,556,994) to ensure accurate calculation of ownership percentages under Disclosure Guidance and Transparency Rules.
- Confirm the percentage of voting rights held in treasury (5.68%) to assess potential dilution or voting power dynamics.
- Review the non-discretionary agreement terms announced on June 4, 2025, to understand the remaining capacity or duration of the current buyback program.
- Note that the filing does not provide updated revenue or earnings metrics; refer to the Q1 2025 results for operational performance.